Category: Bentracimab

PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab

Shots: BioVectra to provide its integrated CDMO services for the manufacturing of API of bentracimab for use in PhaseBio’s ongoing global studies and global commercial use upon regulatory approval PhaseBio plans to integrate API manufactured at a commercial scale at BioVectra into the ongoing P-IIb and P-III REVERSE-IT study to support the global regulatory filings […]

PhaseBio Reports First Patients Dosing in its P-III REVERSE-IT Study of Bentracimab in Canada

Shots: The company has reported the expansion of its P-III REVERSE-IT study for bentracimab in Canada where the first patients from major health centers globally have been enrolled (approx. 200 patients) and dosed Bentracimab demonstrated sustained reversal of the antiplatelet activity of Brilinta (ticagrelor). In a translational study, bentracimab achieved equivalent reversal of branded ticagrelor […]